APA (7th ed.) Citation

Tai, T., Tsai, Y., Shih, C., Li, C., Chang, Y., Huang, C., . . . Wu, C. (2023). Refracture risk and all-cause mortality after vertebral fragility fractures: Anti-osteoporotic medications matter. Journal of the Formosan Medical Association, 122, S65-S73. https://doi.org/10.1016/j.jfma.2023.04.004

Chicago Style (17th ed.) Citation

Tai, Ta-Wei, et al. "Refracture Risk and All-cause Mortality After Vertebral Fragility Fractures: Anti-osteoporotic Medications Matter." Journal of the Formosan Medical Association 122 (2023): S65-S73. https://doi.org/10.1016/j.jfma.2023.04.004.

MLA (9th ed.) Citation

Tai, Ta-Wei, et al. "Refracture Risk and All-cause Mortality After Vertebral Fragility Fractures: Anti-osteoporotic Medications Matter." Journal of the Formosan Medical Association, vol. 122, 2023, pp. S65-S73, https://doi.org/10.1016/j.jfma.2023.04.004.